Skip to main content

Table 2 Multiple linear regression analysis between insulin sensitivity and secretion indices and glucose control parameters before randomization

From: Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

  HbA1c Fasting plasma glucose AUCglu
β 95% CI P β 95% CI P β 95% CI P
DI120 −0.784 (−0.053,-0.014) 0.001* −0.426 (−1.053,-0.148) 0.011* −0.525 (−14.088,-2.496) 0.006*
HOMA-β (%) 0.005 (−0.010,0.011) 0.979 −0.507 (−0.752,-0.262) <0.001* −0.348 (−7.040,-0.759) 0.016*
Insulinogenic index30 (pmol/mmol) 0.341 (−0.001,0.014) 0.075 0.211 (−0.038,0.303) 0.124 0.016 (−2.074,2.296) 0.919
HOMA-IR −0.068 (−0.223,0.165) 0.764 0.484 (2.168,11.302) 0.005* 0.128 (−38.411,78.513) 0.492
MISI 0.270 (−0.111,0.488) 0.210 0.037 (−6.204,7.882) 0.811 −0.021 (−95.634,84.672) 0.903
  1. Adjusted for age, gender, body mass index, and disease duration. *P < 0.05.
  2. AUCglu, area under curve of glucose in 120 min; DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index;
  3. HOMA-IR, homeostasis model assessment insulin resistance index; MISI, Matsuda insulin sensitivity index.